Cel Sci Business Update
CEL-SCI's cancer immunotherapy Multikine has been granted designation under the Saudi Food and Drug Authority’s (SFDA) New Accelerator Program for Drugs in Rare Diseases (NADR). This designation, submitted by partner Amarox, allows for a priority 160-working-day review of a forthcoming Marketing Authorization Application, potentially making Saudi Arabia the first commercial market for the drug in 2027 or 2028.
- Counterparty
- Amarox